Published in Rev Panam Salud Publica on April 01, 2007
The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg (2010) 4.09
Evaluation of the diagnostic utility of the traditional and revised WHO dengue case definitions. PLoS Negl Trop Dis (2013) 0.95
Conditions of the household and peridomicile and severe dengue: a case-control study in Brazil. Infect Ecol Epidemiol (2014) 0.75
China's three-year health reform program and equity in sanitation improvement: a panel analysis. BMC Public Health (2015) 0.75
The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination. PLoS Negl Trop Dis (2008) 5.30
The epidemiology of dengue in the americas over the last three decades: a worrisome reality. Am J Trop Med Hyg (2010) 4.09
Prevention, control, and elimination of neglected diseases in the Americas: pathways to integrated, inter-programmatic, inter-sectoral action for health and development. BMC Public Health (2007) 2.78
Evaluation of commercially available anti-dengue virus immunoglobulin M tests. Emerg Infect Dis (2009) 2.26
Diagnosis of dengue virus infection by detection of specific immunoglobulin M (IgM) and IgA antibodies in serum and saliva. Clin Diagn Lab Immunol (2003) 2.22
Elimination of neglected diseases in latin america and the Caribbean: a mapping of selected diseases. PLoS Negl Trop Dis (2011) 1.75
IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba. J Med Virol (2004) 1.50
HLA-A, -B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of dengue 2 disease: advantages of the Cuban population for HLA studies of dengue virus infection. Hum Immunol (2007) 1.29
A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine (2006) 1.24
Apoptosis in tissues from fatal dengue shock syndrome. J Clin Virol (2007) 1.23
PCR detection of dengue virus using dried whole blood spotted on filter paper. J Virol Methods (2005) 1.14
Elimination of rubella and congenital rubella syndrome in the Americas: another opportunity to address inequities in health. Rev Panam Salud Publica (2004) 1.13
Dengue 3 epidemic, Havana, 2001. Emerg Infect Dis (2004) 1.10
Measles and rubella eradication in the Americas. Vaccine (2011) 1.03
Asymptomatic dengue infection in a Cuban population confirms the protective role of the RR variant of the FcgammaRIIa polymorphism. Am J Trop Med Hyg (2010) 1.02
Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res (2008) 1.00
[Economic impact of dengue 2 epidemic in Santiago de Cuba, 1997]. Rev Cubana Med Trop (2005) 0.98
Primary and secondary infections of Macaca fascicularis monkeys with Asian and American genotypes of dengue virus 2. Clin Vaccine Immunol (2007) 0.97
Diagnosis of dengue virus infection by the visual and simple AuBioDOT immunoglobulin M capture system. Clin Diagn Lab Immunol (2003) 0.97
The global inter-relatedness of disease control. Lancet Infect Dis (2007) 0.96
Anticipating new vaccines in the Americas. Rev Panam Salud Publica (2004) 0.95
Ethnicity and difference in dengue virus-specific memory T cell responses in Cuban individuals. Viral Immunol (2006) 0.95
Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res (2006) 0.94
Fatal severe dengue and cell death in sickle cell disease during the 2001-2002 Havana dengue epidemic. Int J Infect Dis (2008) 0.93
A novel fusion protein domain III-capsid from dengue-2, in a highly aggregated form, induces a functional immune response and protection in mice. Virology (2009) 0.93
Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins. Arch Virol (2008) 0.93
[Society, economy, inequities and dengue]. Rev Cubana Med Trop (2013) 0.92
Long-term memory cellular immune response to dengue virus after a natural primary infection. Int J Infect Dis (2002) 0.91
Association of MICA and MICB alleles with symptomatic dengue infection. Hum Immunol (2011) 0.88
Antibody responses to Asian and American genotypes of dengue 2 virus in immunized mice. Clin Diagn Lab Immunol (2005) 0.87
Oxidative stress in adult dengue patients. Am J Trop Med Hyg (2004) 0.87
A dengue-2 Envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods (2004) 0.87
A myocarditis outbreak with fatal cases associated with adenovirus subgenera C among children from Havana City in 2005. J Clin Virol (2008) 0.86
Immunological evaluation in nonhuman primates of formulations based on the chimeric protein P64k-domain III of dengue 2 and two components of Neisseria meningitidis. Vaccine (2008) 0.85
Guanacaste, Costa Rica: a landmark for cervical cancer prevention. Rev Panam Salud Publica (2004) 0.85
The chimeric protein domain III-capsid of dengue virus serotype 2 (DEN-2) successfully boosts neutralizing antibodies generated in monkeys upon infection with DEN-2. Clin Vaccine Immunol (2011) 0.83
Apoptosis, vascular leakage and increased risk of severe dengue in a type 2 diabetes mellitus patient. Diab Vasc Dis Res (2008) 0.83
A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem (2004) 0.83
Unequivocal regional support for Margaret Chan's commitment to primary health care. Lancet (2008) 0.82
Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. Int J Infect Dis (2009) 0.82
Dual infection with hepatitis A and E viruses in outbreaks and in sporadic clinical cases: Cuba 1998-2003. J Med Virol (2008) 0.82
Serotype-specificity of recombinant fusion proteins containing domain III of dengue virus. Virus Res (2008) 0.81
A recombinant capsid protein from Dengue-2 induces protection in mice against homologous virus. Vaccine (2006) 0.81
Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice. Int Immunol (2009) 0.80
The two component adjuvant IC31® potentiates the protective immunity induced by a dengue 2 recombinant fusion protein in mice. Vaccine (2011) 0.80
Purified and highly aggregated chimeric protein DIIIC-2 induces a functional immune response in mice against dengue 2 virus. Arch Virol (2012) 0.79
Variation in inflammatory/regulatory cytokines in secondary, tertiary, and quaternary challenges with dengue virus. Am J Trop Med Hyg (2012) 0.78
The fusion site of envelope fragments from each serotype of Dengue virus in the P64k protein, influence some parameters of the resulting chimeric constructs. Biochem Biophys Res Commun (2003) 0.78
Prevalence of febrile syndromes in dengue surveillance, havana city, 2007. MEDICC Rev (2011) 0.78
Mental health: a public health priority in the Americas. Rev Panam Salud Publica (2005) 0.77
Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice. J Gen Virol (2012) 0.77
A tetravalent dengue vaccine containing a mix of domain III-P64k and domain III-capsid proteins induces a protective response in mice. Arch Virol (2014) 0.77
Expression in Pichia pastoris and immunological evaluation of a truncated Dengue envelope protein. Mol Biotechnol (2007) 0.77
Dengue-4 envelope domain III fused twice within the meningococcal P64k protein carrier induces partial protection in mice. Biotechnol Appl Biochem (2009) 0.77
Recombinant dengue 2 virus NS3 protein conserves structural antigenic and immunological properties relevant for dengue vaccine design. Virus Genes (2014) 0.77
Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol (2014) 0.76
A standard method for measuring blood pressure in the Americas. Rev Panam Salud Publica (2003) 0.75
Biological and Molecular Properties of Dengue 2 Strains Isolated during the DHF/DSS Cuban Epidemic, 1981. Int J Biomed Sci (2007) 0.75
PAHO fighting AIDS. Lancet (2003) 0.75
Rapid diagnosis of pandemic (H1N1) 2009 in Cuba. Emerg Infect Dis (2012) 0.75
The serogroup A capsular polysaccharide from Neisseria meningitidis enhances the cell-mediated immunity and the protective capacity induced by a dengue fusion protein in mice. Arch Virol (2012) 0.75
The role of disease-specific research: a developing-country perspective. MEDICC Rev (2009) 0.75
[Detection of lymphoproliferative response in monkeys innoculated with dengue 4 virus]. Rev Cubana Med Trop (2005) 0.75
Serotype specificity of recombinant fusion protein containing domain III and capsid protein of dengue virus 2. Antiviral Res (2012) 0.75
[Low-affinity Fcγ receptor IIa gene polymorphism and dengue bleeding disorder]. Enferm Infecc Microbiol Clin (2012) 0.75
Guatemala never again: progress and challenges in the protection of research subjects. Rev Panam Salud Publica (2011) 0.75
A century in public health. Bull World Health Organ (2006) 0.75
[The framework convention on tobacco control: a milestone in public health history]. Rev Panam Salud Publica (2003) 0.75
[Development of new vaccines: information production for decision making]. Rev Panam Salud Publica (2004) 0.75
[Dengue and hemorrhagic dengue fever: a forgotten entity?]. Rev Cubana Med Trop (2005) 0.75
Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus. Arch Virol (2010) 0.75